Teva Pharmaceutical Industries Ltd. ADR logo

Teva Pharmaceutical Industries Ltd. ADR (TEVA)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
28. 46
+0.05
+0.19%
$
30.82B Market Cap
- P/E Ratio
0.34% Div Yield
8,529,387 Volume
- Eps
$ 28.41
Previous Close
Day Range
28 28.68
Year Range
12.47 28.68
Want to track TEVA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 52 days
Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 2 days ago
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 4 days ago
Teva seeks startups to help solve global pharmaceutical challenges

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceuticals industry.

Reuters | 2 weeks ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies London Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited ( TEVA ) Jefferies London Healthcare Conference 2025 November 18, 2025 6:00 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Welcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies.

Seekingalpha | 2 weeks ago
Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited (TEVA) Presents at UBS Global Healthcare Conference 2025 Transcript

Teva Pharmaceutical Industries Limited ( TEVA ) UBS Global Healthcare Conference 2025 November 10, 2025 8:45 AM EST Company Participants Richard Francis - President, CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

Seekingalpha | 3 weeks ago
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 3 weeks ago
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year?

Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Brainsway Ltd.

Zacks | 4 weeks ago
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up

Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.

Zacks | 1 month ago
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.

Youtube | 1 month ago
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 1 month ago
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks | 1 month ago
Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Ethic Inc.

Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Ethic Inc.

Ethic Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 7.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,490 shares of the company's stock after selling 1,399 shares during the quarter. Ethic Inc.'s holdings in

Defenseworld | 1 month ago
Loading...
Load More